Answers are grounded in this paper and cite their sources.
OBJECTIVE: Lu-DOTATATE) after the failure of somatostatin analogues. METHODS: Lu-DOTATATE treatment to assess the progression-free survival (PFS). RESULTS: The responses of the patients were evaluated as partial response in 8 (32%) patients, stable disease in 12 (48%), and progressive disease in 5 (20%). The median PFS was 18 months; longer than this threshold in 14 patients (26.0 months) and shorter in 11 (8.4 months). The mean SUVmax of metastases in the liver (34.15±17.89 vs. 14.69±9.17, P=0.004) and mean SUVmax of all body metastatic lesions (33.05±14.32 vs. 15.26±4.84, P=0.001) were higher in patientswith longer PFS. The tumor grade, the origin of the tumor, Ki67 status, and previous somatostatin treatment history were not significantly different between the two PFS groups. CONCLUSION: Lu-DOTATATE treatment, and could be a useful parameter for the treatment selection.
No takes yet. Share an insight, caveat, or question.
Teker et al. (2022) studied this question.